S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Phase 3 Active not recruiting 1939 enrolled SWOG Cancer Research Network National Cancer Institute (NCI) · collab

RandomizedParallel-groupDouble-blindTreatment

Summary

RATIONALE: Estrogen can cause the growth of breast cancer cells. Hormone therapy using tamoxifen citrate, goserelin acetate, leuprolide acetate, anastrozole, letrozole, or exemestane, may fight breast cancer by lowering the amount of estrogen the body makes. Everolimus may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet know whether hormone therapy is more effective when given with or without everolimus in treating breast cancer. PURPOSE: This randomized phase III trial studies how well giving hormone therapy together with or without everolimus work in treating patients with breast cancer.

Timeline

Start: 2013-09-12
Primary completion: 2022-12-01
Completion: 2030-01

Publications

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Everolimus	Small molecule	10 mg	Oral
Background	Anastrozole	Other / unclassified	—	Oral
Background	Exemestane	Small molecule	—	Oral
Background	Goserelin	Other / unclassified	—	Subcutaneous
Background	Letrozole	Other / unclassified	—	Oral
Background	Leuprolide	Other / unclassified	—	Subcutaneous
Background	Tamoxifen	Small molecule	—	Oral

S1207 Hormone Therapy With or Without Everolimus in Treating Patients With Breast Cancer

Summary

Timeline

Publications

Drugs

Indications